MedTrace Logo

Effects of Carboplatin and Gemcitabine on Stage IIIB Pleural Effusion and Stage IV Lung Cancer

NCT00247416 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2014-03-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to find better treatment for lung cancer and to find out what effects the combined treatment of carboplatin and gemcitabine when given with or without dexamethasone have on cancer.

This study will determine if dexamethasone, when given before standard chemotherapy will increase the cancer fighting effects and reduce the side effects of chemotherapy.

Conditions

  • Stage IV Non-small Cell Lung Cancer
  • Stage IIIB Non-small Cell Lung Cancer

Interventions

DRUG

Gemcitabine

Gemcitabine 1000 mg/m\^2 intravenously over 30 minutes on days 5 and 12.

DRUG

Dexamethasone

16 mg bid for 4 days prior to each chemotherapy start.

DRUG

Carboplatin

AUC 6.0 intravenously over 30 minutes on day 5.

Sponsors & Collaborators

  • Kentucky Lung Cancer Research Program

    collaborator OTHER

  • Susanne Arnold

    lead OTHER

Principal Investigators

  • John Rinehart · Lucille P. Markey Cancer Center at University of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-08-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00247416 on ClinicalTrials.gov